| Business Summary | | CV
Therapeutics,
Inc
is
a
biopharmaceutical
company
engaged
in
the
discovery
and
development
of
new
small-molecule
drugs
to
treat
cardiovascular
disease.
The
Company
is
conducting
clinical
trials
for
three
of
its
drug
candidates.
Ranolazine,
the
first
in
a
new
class
of
compounds
known
as
partial
fatty
acid
oxidation
(pFOX)
inhibitors,
is
in
Phase
III
clinical
trials
for
the
potential
treatment
of
chronic
angina.
CVT-510,
an
A1
adenosine
receptor
agonist,
is
in
Phase
II
clinical
trials
for
the
potential
treatment
of
atrial
arrhythmias.
CVT-3146,
an
A2A
adenosine
receptor
agonist,
is
in
Phase
I
clinical
trials
for
the
potential
use
as
an
adjunctive
pharmacologic
agent
in
cardiac
perfusion
imaging
studies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CV
Therapeutics
is
a
biopharmaceutical
company
engaged
in
the
discovery
and
development
of
new
small
molecule
drugs
to
treat
cardiovascular
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
42%
to
$2.8
million.
Net
loss
totaled
$34.5
million,
up
from
$14.5
million.
Revenues
reflect
the
milestone
payment
from
Biogen,
Inc.
Higher
loss
reflects
greater
external
costs
associated
with
the
Company's
clinical
programs
and
increased
personnel
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Louis Lange, M.D., Ph.D., 52 Chairman
and CEO | $548K | $1.8M | Daniel Spiegelman, 42 CFO,
Sr. VP | 318K | 2.5M | Andrew Wolff, M.D., 46 Sr.
VP, Clinical R&D | 330K | 1.6M | Tricia Suvari, J.D., 40 VP,
Gen. Counsel, Assistant Sec. | -- | -- | David McCaleb, 48 VP
of Marketing | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|